Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression

Treatment-resistant Depression Clinical Trial

— ACOUSTIM  

Official title:

Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03701724
• Other study ID #: RC17_0494
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 5, 2018
• Est. completion date: December 30, 2023

Study information

• Verified date: September 2022
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment resistant depression (TRD) is a frequent, debilitating condition mostly treated by antidepressants. Repeated magnetic transcranial stimulation (rTMS) has proven adjuvant efficacy in TRD in the acute phase of treatment with a very good tolerance and acceptability. Maintenance rTMS (mTMS) is a strategy consisting in adding regular single TMS sessions after response to an acute course in order to keep the benefit of initial treatment over several month or years. Demonstrating that rTMS is efficient to improve long-term prognosis and decrease economic burden would have a tremendous impact in clinical practice in psychiatry. Thus the investigator's aim is to analyze the long term impact of mTMS treatment on costs, but also quality of life and clinical issues.

Description:

TRD is associated with enormous social, economic, and personal costs. In literature, psychosocial and pharmacological interventions showed limited one year long-term efficacy in terms of relapse (only 10% of sustained remission at one-year follow-up actually) and quality of life due to refractoriness, observance and adverse effects. In the recent years the field of non-invasive brain stimulation became more mature with an increasing level of evidence reaching Level 1 for rTMS as curative treatment for depression in international guidelines. It is a safe and well tolerated treatment but with still high relapse rate at 6 month and one year (comparable to those former described for ECT). mTMS is a promising tool (as it was proven for ECT) to achieve sustained response several month after treatment in a significant proportion of patients. Little is known about its long-term economic and social benefit which is a crucial question given its time consuming nature. To date there is no large Randomized Clinical Trial (RCT) assessing the long-term health economic interest or adjuvant mTMS compared to treatment as usual (TAU) alone in unipolar TRD . This study is a double-blind randomized controlled trial aiming at determining a 12 month cost-utility analysis, according to collective perspective, of two different modalities of rTMS (systematic mTMS or curative rTMS in case of relapse) for TRD compared to TAU alone. The secondary aims are to describe 24 month cost-utility, longitudinal clinical issues in terms of mood and quality of life, prognosis factors, as well as TAU actual strategies in that population.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 119
• Est. completion date: December 30, 2023
• Est. primary completion date: December 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 MADRS >19

• Episode duration: 12 weeks to 3 years.

• 2 to 4 unsuccessful treatment lines (including antidepressants, and potentialization agents lithium and quetiapine) despite adequate dosage and duration (6 weeks stable posology)

• Ability to consent and express informed consent, to answer questionnaires and to go to follow-up visits.

• Affiliation to social security

Exclusion Criteria:

• Bipolar disorder

• Schizophrenia and other psychotic disorders

• Mental retardation or developmental disorder

• Substance abuse or dependence

• Depression symptoms better explained by medical conditions

• Neurologic conditions (e.g.,previous epilepsy or unexplained seizures, stroke, trauma, infection, metabolic disease, severe migraines, multiple sclerosis, brain tumor)

• Presence of at least one contra-indication to rTMS

• Pregnancy/breast-feeding

• Patient who previously received 5 lines or more pharmacological treatment for the current episode (excluding symptomatic psychotropic drugs, e.g. benzodiazepines and hypnotics)

• Former use of electroconvulsive therapy or rTMS within the current episode.

• Previous failure of adequate ECT (at least 12 well conducted sessions) or rTMS course (at least 20 well conducted sessions) in the medical history.

• History of at least two courses of ECT, previous need for maintenance ECT.

• Protection measure : maintenance of justice, tutelage, legal guardianship

• Woman of childbearing age without effective contraception

• Liberty deprivation (e.g. incarceration, therapeutic injunction)

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Treatment-Resistant
• Treatment-resistant Depression

Intervention

Device:
• Systematic maintenance rTMS
Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
• rTMS course in case of relapse
Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
• sham rTMS
The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.

Locations

Country	Name	City	State
France	CHU d'Angers	Angers
France	CHRU de Besançon	Besançon
France	CH le Vinatier Lyon	Bron
France	CHU de Caen	Caen
France	CHU de Clermont-Ferrand	Clermont-Ferrand
France	CHU de Dijon	Dijon
France	Clinique de Vontes	Esvre-sur-Indre
France	EPSM de Lille	Lille
France	CH Esquirol - Limoges	Limoges
France	CHU de Montpellier	Montpellier
France	Nantes University Hospital	Nantes
France	EPS de Ville-Evrard	Neuilly-sur-Marne
France	GH PItié Salpétrière	Paris
France	GHU Psychiatrie Ste Anne	Paris
France	CH Henri Laborit (Poitiers)	Poitiers
France	Centre hospitalier Guillaume Regnier Rennes	Rennes
France	CH du Rouvray - Rouen	Rouen
France	CHU de Toulouse	Toulouse
France	CHU de Tours / CHRU de Tours	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cost-utility ratio, according to collective perspective of rTMS use in TRD compared to conventional therapeutic approaches without active rTMS.	The utility will be measured by : Quality Adjusted Life Year (QALYs) as estimated from responses to the Euroqol-5 Dimensions (EQ-5D) health-related quality of life questionnaire. The questionnaire focuses on 5 dimensions: mobility, personal autonomy, current activities, pain/discomfort and anxiety/depression. For each of these dimensions, 3 answers are possible.; The costs will be measured by the addition of the following costs: Drugs dispensing via Health insurance database "National system of information of the French health insurance" (SNIIRAM), hospitalizations, work stoppages and care consumption collected in a declarative patient questionnaire.	12 months
Secondary	Cost-utility ratio, according to collective perspective of rTMS use in TRD compared to conventional therapeutic approaches without active rTMS.	Quality Adjusted Life Year (QALYs) as estimated from responses to the Euroqol-5 Dimensions (EQ-5D) health-related quality of life questionnaire; The costs will be measured by the additional of the following costs: Drugs dispensing via Health insurance database SNIIRAM, hospitalizations, work stoppages and care consumption collected in a declarative patient questionnaire	24 months
Secondary	Budget impact analysis of spreading the most efficient strategy for using rTMS (systematic mTMS or rTMS course in case of relapse).	Comparison of intervention costs on the study sample and projection of these costs over 5 years, from the health insurance and hospital perspectives	5 years
Secondary	Major depressive disorder history	This outcome will be assessed by patient interview, with the following data (not exhaustive): date of initial symptoms, length of the current episode, family antecedents of mood disorders.	Baseline
Secondary	Level of depression treatment-resistance	Maudsley Staging model score: a multidimensional tool to quantify treatment resistance in depression. It evaluates 5 dimensions: 1) length of the current depressive episode, 2) symptomatic intensity, 3) failure of the antidepressant drugs, 4) Increase treatment 5) use of Electro-convulsive therapy. The total score ranges from 3 to 15. 15 being the highest level of treatment resistance.	Baseline
Secondary	professional status	patient's professional status (active, unemployed, retired...)	Baseline,12 months and 24 months
Secondary	marital status	patient's marital status (married, widow, single...)	Baseline,12 months and 24 months
Secondary	Response rate	Response is defined as follows: decrease of the MADRS score by at least 50% compared to baseline score. MADRS stands for Montgomery-Asberg Depression Rating Scale. It is used to measure the severity of depressive episodes in patients with mood disorders. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A score from 0 to 6 being normal/symptom absent and a score >34 being severe depression.	12 months and 24 months
Secondary	Remission rate	Remission is defined as follows: MADRS score = 10 (see detailed description of MADRS in outcome 8)	12 months and 24 months
Secondary	Relapse-free survival	Number of patients with no relapse. Relapse is defined as follows: MADRS = 20 (see detailed description of MADRS in outcome 8)	12 months and 24 months
Secondary	MADRS score	MADRS score (see detailed description of MADRS in outcome 8)	Baseline, 2 months, 6 months , 9 months, 12 months, 18 months, 24 months
Secondary	Beck Depression Inventory (BDI) score	The BDI is 13-item multiple-choice self-report inventory, for measuring the severity of depression. The global score is an addition of each item's score and ranges from 0 (minimal depression) to 39 (severe depression).	Baseline, 2 months, 6 months , 9 months, 12 months, 18 months, 24 months
Secondary	Clinical Global Impression (CGI) score	The Clinical Global Impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders. Each scale is rated from 0 to 7. 0 being the best level and 7 the worst level.	Baseline, 2 months, 6 months , 9 months, 12 months, 18 months, 24 months
Secondary	Adverse events linked to the medical treatment for depression	Number and types of adverse events linked to the medical treatment for depression	24 months
Secondary	Declarative drug compliance via the MARS (Medication Adherence Report Scale)	MARS is the Medication Adherence Report Scale, including 10 questions, the global score ranges from 0 to 10, 0 corresponds to the worst drug compliance and 10 to an excellent drug compliance	baseline, 12 months and 24 months
Secondary	Declarative drug compliance via the CRS (Clinician Rating Scale)	CRS is the Clinician Rating Scale , including 7 questions, the global score ranges from 1 to 7, 7 being the worst level of drug compliance.	baseline, 12 months and 24 months
Secondary	Treatment(s) switch(es)	Number of treatment switches per patient	Baseline, 2 months, 6 months , 9 months, 12 months, 18 months, 24 months
Secondary	Treatment(s) dose increase	Number of drug(s) dose(s) increases prescribed to the patient	Baseline, 2 months, 6 months , 9 months, 12 months, 18 months, 24 months
Secondary	Treatments combination(s)	List of drugs (name) prescribed to the patient	Baseline, 2 months, 6 months , 9 months, 12 months, 18 months, 24 months
Secondary	Rate of suicide attempts and suicides	number of suicide attempts and suicides per patient	12 months and 24 months
Secondary	Patient's quality of life	Short-Form 36 (SF 36) questionnaire: instrument used to assess multidimensional health-related quality of life, which measures 8 health related parameters: physical function, social function, physical role, emotional role, mental health, energy, pain, general health perceptions	baseline,12 months and 24 months
Secondary	Response rate at the end of rTMS courses	Response is defined as follows: decrease of the MADRS score by at least 50% compared to baseline score (see detailed description of MADRS in outcome 8)	1 month after each rTMS treatments
Secondary	Remission rate at the end of rTMS courses	Remission is defined as follows: MADRS score = 10 (see detailed description of MADRS in outcome 8)	1 month after each rTMS treatments
Secondary	Number of days between the successive rTMS courses	Number of days between end of rTMS course X and beginning of course X+1, for each patient	24 months
Secondary	Total number of rTMS sessions	total number of rTMS sessions per patient	24 months
Secondary	Time between relapses	Number of days between relapses, per patient	24 months
Secondary	Compliance with rTMS	number of missed sessions over the number of planned sessions, per patient	24 months
Secondary	Patient acceptability of the rTMS technique: Analog Visual Scale	Analog Visual Scale of acceptability of the rTMS completed by the patient, ranging from 0 to 10. 0 being "not acceptable" and 10 being "totally acceptable"	24 months